Open Label, Phase 2 Study for Evaluating the Feasibility, Safety and Efficacy of Psychotherapy Assisted Psilocybin for Treatment of Severe Obsessive Compulsive Disorder (OCD) in Drug and/or Psychotherapy Resistant Patients. - Beersheva Mental Health Center (ClinicalTrials.gov, 2025)

Pharmacotherapy to Prevent Alcohol Relapse in Alcohol-Associated Liver Disease. - Zhang W; Hwang SY; Luther J. (2025)

Salience, sensemaking, and setting in psilocybin microdosing - Oblak; Aleš; Hudnik Korošec; Liam; Levačić; Anja; Elersič; Kristian; Pregelj; Peter; Bon; Jurij (Repository of the University of Ljubljana (University of Ljubljana), 2025)

Psilocybin-Assisted vs Ketamine-Assisted Psychotherapy for Alcohol Use Disorder - Peggy C Nopoulos (ClinicalTrials.gov, 2025)

Psilocybin Experiential Therapist Training: Insights from a World-First Study - Ioakimidis-MacDougall G; Gardner J; Liknaitzky P. (medRxiv, 2025)

Standardization of Psilocybin Dosing in a Natural Product-Based Retreat Setting: A Practical Method for Dose Quantification and Adjustment Across Sessions - Rosal SRP; Faber SC. (Research Square, 2025)

Unmixing the Psychedelic Connectome: Brain Network Traits of Psilocybin - Bhavaraju KP; Mason NL; Mallaroni P; Heinke D; Toennes SW; Ramaekers JG; Amico E. (bioRxiv, 2025)

Microdosing Psilocybin for Major Depressive Disorder: Study Protocol for a Phase II Double-Blind Placebo-Controlled Randomized Partial Crossover Trial (PsyArXiv, 2025)

Qualitative insights into psilocybin and LSD experiences: Enhanced connection and emotion processing reported by Spanish-speaking survey respondents - Meghan DellaCrosse; Shoval Gilead; Rafael Lancelotta; Ana María Ortiz Bernal; Christopher Timmermann; Alan K. Davis (Psychedelics, 2025)

Comparative Efficacy of Psilocybin and MDMA in PTSD Treatment: A Systematic Review of Long-Term Outcomes - Presley Aspen; Presley Pham; Jennifer Mitchell (Berkeley Scientific Journal, 2025)

Negative affective bias in depression following treatment with psilocybin or escitalopram - a secondary analysis from a randomized trial - Marieke Martens; Bruna Giribaldi Cunha; David Erritzøe; David Nutt; Robin Carhart-Harris; Catherine J. Harmer (Translational Psychiatry, 2025)

Acute Kidney Failure and Myocarditis Triggered by Magic Mushroom Toxicity in a Patient With Prior Cocaine Exposure - Aung Phyo Oo; Sarah Tseu; Arvind Ponnusamy (Cureus, 2025)

‘Magic’ mechanisms underlie psilocybin’s effects in chronic pain - Sian Lewis (Nature reviews. Neuroscience, 2025)

Pharmacodynamic biomarker - or psychotherapeutic process? Comment on “The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression” - Max Wolff; Samuli Kangaslampi (Journal of Affective Disorders, 2025)

Novel qNMR Methodto Quantify Psilocybin and Psilocinin Psychedelic Mushrooms - Luisina Rodríguez (12333694); Guillermo Morera (22593717); Sandra Lupo (22593720); Danilo Davyt (2738347); Ignacio Carrera (1677175); Gonzalo Hernández Dossi (22593723) (Figshare, 2025)

Novel qNMR Method to Quantify Psilocybin and Psilocin in Psychedelic Mushrooms - Luisina Castelli Rodríguez; Guillermo Morera; Sandra Lupo; Danilo Davyt; Ignacio Carrera; Gonzalo Hernández Dossi (ACS Omega, 2025)

The Psychedelic Psilocin Suppresses Activity of Central Amygdala Corticotropin-Releasing Factor Receptor 1 Neurons and Decreases Ethanol Drinking in Female Mice - Sarah N. Magee; Allison C. Sereno; Maria Echeveste-Sanchez; Elizabeth G. Shannon; Abir Mohsin; Sarah E. Mott; Sara Faccidomo; Clyde W. Hodge; Melissa A. Herman (Journal of Neuroscience, 2025)

Engineering the Next Generation of Psychedelic Therapeutics through Serotonergic Precision and Pharmacokinetic Control. - Renner AC; Kargbo RB. (2025)

The Relationship Between Psychedelic Use and Alcohol Use Disorder in a Nationally Representative Sample. - Zech JM; Richard J; Jones GM (Journal of psychoactive drugs, 2025)

Ketamine and Psilocybin Differentially Impact Sensory Learning During the Mismatch Negativity - Allohverdi SG; Soltanzadeh M; Schmidt A; Charlton CE; Hauke DJ; Karvelis P; Vollenweider FX; Diaconescu AO. (bioRxiv, 2025)

Efficacy, all-cause discontinuation, and safety of serotonergic psychedelics and MDMA to treat mental disorders: A living systematic review with meta-analysis. - Højlund M; Kafali HY; Kırmızı B; Fusar-Poli P; Correll CU; Cortese S; Sabé M; Fiedorowicz J; Saraf G; Zein J; Berk M; Husain MI; et al. (2025)

A single dose of psilocybin alleviates chronic pain and associated anxiety and depression in mice - AccessScience Editors (2025)

Correction: Acute and long-term effects of psilocybin on energy balance and feeding behavior in mice. - Fadahunsi N; Lund J; Breum AW; Mathiesen CV; Larsen IB; Knudsen GM; Klein AB; Clemmensen C. (2025)

Divergent effects of ketamine and psilocybin on EEG power spectral density in a mismatch negativity paradigm - Milad Soltanzadeh; Zheng Wang; Shona G. Allohverdi; Colleen E. Charlton; André Schmidt; Franz Xaver Vollenweider; Andreea O. Diaconescu (Universität Zürich, ZORA, 2025)

Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive Disorder - Yale University (ClinicalTrials.gov, 2025)

A Phase 1/2 Study of a Group Model of Psilocybin-Assisted Therapy for Cancer-Related Anxiety in Patients With Metastatic Cancer - University of Washington (ClinicalTrials.gov, 2025)

Psilocybin reduces depressive-like behavior and improves cognition in healthy aging mice via epigenetic regulation of plasticity- and immune-related genes - Mennenga S; Hanson T; Semple M; Lifshitz D; Flores B; Balducci J; Harker S; Ford A; Lewis C. (Research Square, 2025)

Psilocybin and chronic neuropathic pain: a systematic review. - Jevotovsky DS; Chopra H; Pak DJ; Durbhakula S; Shustorovich A; Juneja T; Broachwala MY; AlFarra T; Silver C; Kreitzer G; Oreoluwa P; Weissman BB; et al. (2025)

Psilocybin Outside the Clinic - Kent E. Hutchison; Jake F. Hooper; Hollis C. Karoly (JAMA Psychiatry, 2025)

Engineering artificial biosynthetic pathways for efficient microbial production of psilocybin and psilocin - Cui Guo; Nguyen N T Luu; Maryem M Adwer; Hamed Hosseinzadeh; Venkatesh Balan; Yajun Yan; Yuheng Lin (Metabolic Engineering, 2025)

Psilocybin mitigates chronic behavioral and neurobiological alterations in a rat model of recurrent intimate partner violence-related brain injury - Josh Allen; Mujun Sun; Tamara L. Baker; Shannon Dames; Pamela Kryskow; Brian R. Christie; Stuart J. McDonald; Sandy R. Shultz (Molecular Psychiatry, 2025)

Psilocybin-assisted physiotherapy for refractory motor functional neurological disorder: protocol for a randomised dose-comparison pilot study - Chiranth Bhagavan; Alexander Bryson; Olivia Carter; Glenn Nielsen; David J. Berlowitz; Sara Issak; Sabine Braat; Sophie Zaloumis; Zachary Attard; Dina Eleftheriadis; Georgina Oliver; Deanne Mayne; et al. (Acta Neuropsychiatrica, 2025)

A Tragedy of Errors: The State of Psychedelic Research in the Treatment of Alcohol Use Disorder. - Srivastava AB; Gold MS (Brain sciences, 2025)

Psilocybin-assisted therapy for demoralisation in hospice patients: feasibility, safety and preliminary efficacy - Yvan Beaussant; Zachary Sager; Caitlin W. Brennan; Isabel Kristan; Michael Ljuslin; Emanuele Mazzola; David R. Macdonald; M. Murphy; Kabir Nigam; Alden Doerner Rinaldi; Justin J. Sanders; Kristen G. Schaefer; et al. (BMJ Supportive & Palliative Care, 2025)

Hormonal Influences on Psilocybin Responsivity Across the Female Lifespan: Toward Personalized Psychedelic-Assisted Therapy - Faith Ekoh; Shanice Rerrie; James Angud; Ersilia Mirabelli (Psychoactives, 2025)

Microdosing psilocybin and its effect on creativity: Lessons learned from three double-blind placebo controlled longitudinal trials - Luisa Prochazkova; Josephine Marschall; Michiel van Elk; Ben David Rifkin; Neil R Schon; Donatella Fiacchino; George Fejer; Martin Kuchař; Bernhard Hommel (Neuropharmacology, 2025)

Lifetime Psychedelic Use and Opioid Use Disorder Severity: Substance-Use Pattern Specific and Mental Health-Dependent Associations in a National Survey (PsyArXiv, 2025)

92. Mushrooms and Mania: Differentiating Psilocybin-Induced Mania From First-Break Bipolar Mania - Tyler D. McGehee; Nicole Lacap; Adeel Iqbal; Alan M. Langlieb (Journal of the Academy of Consultation-Liaison Psychiatry, 2025)

CNSC-36. PSILOCYBIN INDUCES SUSTAINED GLIOMA GROWTH THROUGH SEROTONERGIC AND TRKB PATHWAYS - Richard Drexler; Belgin Yalçın; Rebecca Mancusi; Abigail Rogers; Kiarash Shamardani; Pamelyn J. Woo; Alexandre Ravel; Yahaya A Yabo; Carlos Alberto Oliveira de Biagi-Junior; Costanza Lo Cascio; Robert C. Malenka; Boris D. Heifets; et al. (Neuro-Oncology, 2025)

Psilocybin bei Alkoholkonsumstörung (Suchttherapie, 2025)

Metaanalyse: Wirksamkeit und Sicherheit von Psilocybin bei Major Depressionen (Fortschritte der Neurologie · Psychiatrie, 2025)

Ketamine and psilocybin for athletes: A therapeutic breakthrough or a slippery slope? - Thomas Zandonai; Sofia Venturini; Ornella Corazza (Performance Enhancement & Health, 2025)

The emotional architecture of the psychedelic brain. - Moujaes F; Rieser NM; Belinger L; Herdener M; Zahid Z; Preller KH (Trends in cognitive sciences, 2025)

The therapeutic use of psychedelic drugs: Legal, policy, and neuroscientific perspectives. - Rahmani S; Crupi R; Riley AL; Davidson T (Pharmacology, biochemistry, and behavior, 2025)

Reporting of side-effects in clinical trials of psilocybin-assisted psychotherapy for psychiatric conditions: systematic review - Jonathon Marinis; Sarah Clarke; Alexandre A. Guerin; Adam J. Guastella; Gillinder Bedi (BJPsych Open, 2025)

Paper spray and direct mushroom spray mass spectrometry methods for the analysis of psycho-neurological disorder toxins - Luo W; Dai Q; van Beek TA; Zuilhof H; Chen B; Chen Z; Salentijn GI. (2025)

Use of psilocybin for chronic pain: a scoping review with current evidence and prospection of literature and technology for future applications - André Leão Dantas; Lara Moreira Jalles Milani; Saulo Gabriel Moreira Falci; João Américo da Silveira; Cristina Pereira Isolan; Lia Dietrich (Caderno Pedagógico, 2025)

Precision Functional Brain Mapping to Understand the Mechanisms of Psilocybin - Washington University School of Medicine (ClinicalTrials.gov, 2025)

Psychedelics and ketamine/esketamine in depressive disorders: biological mechanisms and associated neuroimaging and clinical changes. - d'Andrea G; Chiappini S; Ciavoni L; Tucci R; Martino F; Semeraro FM; Di Battista D; Mosca A; Miuli A; Di Carlo F; Russo M; Di Petta G; et al. (2025)

Psilocybin use in bipolar disorder: A comprehensive review. - Do A; Cloutier L; Hébert-Tremblay L; Thauvin C. (2025)

A Randomized, Double-Blind, Placebo-Controlled Mechanistic Study to Assess a Single Oral Dose of CYB003 in Participants With Major Depressive Disorder (MDD) and Moderate to Severe Anxiety - Ohio State University (ClinicalTrials.gov, 2025)

Psilocybin as a fast-acting and long-lasting antidepressant for adolescence: Proposing NeuroD1 as a biomarker of its long-term plasticity - Rubén García-Cabrerizo; Itziar Beruete-Fresnillo; Pedro Bergas-Cladera; M. Julia García-Fuster (Biomedicine & Pharmacotherapy, 2025)

A Wellcome Leap for the Opioid Crisis: Can the 5HT2A Agonist Psilocybin Improve Brain, Behavioral, and Clinical Outcomes in Opioid Use Disorder (OUD)? - Anna Rose Childress; Ph.D. (ClinicalTrials.gov, 2025)

Psilocybin's effects on obsessive-compulsive behaviors: A systematic review of preclinical and clinical evidence - James J Gattuso; Bilgenur Bezcioglu; Carey Wilson; Kato Havaux; Anthony J. Hannan; Thibault Renoir (Psychedelics., 2025)

Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) therapy for patients with advanced cancer: protocol for a multi-method feasibility trial - Candice Richardson; Cindy Chan; Emily Macgregor; Crystal Hare; Breffni Hannon; SarahRose Black; Evan E. Schneider; Daniel Z. Buchman; Stella Wang; Valeria E. Rac; Lusine Abrahamyan; Ella Huszti; et al. (Pilot and Feasibility Studies, 2025)

A Systematic Review and Meta-Analysis Investigating the Efficacy of Various Psychedelic Drugs for the Treatment of Substance Use Disorder. - Keighley EE; Abo Hamza E; Bedewy DA; Nalla S; Moustafa AA. (2025)

Adverse event reporting and management in psilocybin therapy clinical trials: A systematic review to guide clinical and research protocol development. - Bukovsky D; Amaev A; Song J; Kyte S; Carmona-Torres E; Ueno F; Deluca V; Strafella AP; Husain MI; Graff-Guerrero A; Gerretsen P. (2025)

Novel Psilocin Derivatives as Serotonergic Psychedelic Agents for Treating CNS Disorders. - Sabnis RW. (2025)

Investigating the Persisting Effects of a Single Dose of Psilocybin on Structural Plasticity in Healthy Older Adults - University of California; Berkeley (ClinicalTrials.gov, 2025)

Investigating the Mechanisms of the Effects of Psilocybin on Visual Perception and Visual Representations in the Brain - University of California; Berkeley (ClinicalTrials.gov, 2025)

Landscape analysis of pre-registered clinical trials involving classical psychedelics. - Uyar A; Forbrich L; Lueken U; Evens R. (2025)

Is there more to magic mushrooms than psilocybin? - special to C EN Mara Johnson-Groh (C&EN Global Enterprise, 2025)

Simulated 5-HT2A receptor activation accounts for the high complexity of brain activity during psychedelic states - Martin HM; Cofre R; Destexhe A. (bioRxiv, 2025)

Psychedelic-induced behavioral and developmental effects on zebrafish: a systematic review. - de Oliveira AL; de Oliveira DP; Dos Santos RG; Hallak JEC. (2025)

Psilocybin in Alcohol Use Disorder Maintains Abstinence Efficacity: A Scoping Review - Suspene J; Huet S; Berteina-Raboin S; Benyamina A; Baril P; Morisset-Lopez S; Serreau R. (Preprints.org, 2025)

Contemplating versus having used psychedelics in bipolar disorder - What makes the difference? - Vale LN; Ibrahim M; Fávaro-Pereira L; Soares JC; Meyer TD. (2025)

Cognitive and subjective effects of psilocybin microdosing: Results from two double-blind placebo-controlled longitudinal trials - Luisa Prochazkova; Josephine Marschall; Dominique P. Lippelt; Neil R Schon; Martin Kuchař; Bernhard Hommel (Neuropharmacology, 2025)

Biological markers of treatment response to serotonergic psychedelic therapies: a systematic review. - Wong S; Jones BDM; Thiyagarajah MT; Sabbah SG; Thompson C; Solmi M; Umer M; Zrenner C; Voineskos D; Rosenblat JD; Mulsant BH; Blumberger DM; et al. (2025)

Analysis of Serotonin in Caenorhabditis Elegans Subjected to Micro-Dosing with Psilocybin| Iris Publishers - Douglas B. Craig (Insights in Chemistry and Biochemistry, 2025)

Phase I Study of the Safety and Adjunctive Effects of Psilocybin in Adults With Opioid Use Disorder Maintained on a Buprenorphine/Naloxone Formulation - University of Wisconsin; Madison (ClinicalTrials.gov, 2025)

Psilocybin exerts differential effects on social behaviour and inflammation in mice in contexts of activity-based anorexia (ABA) - Shadani S; Greaves E; Andrews ZB; Foldi CJ. (bioRxiv, 2025)

A Phase 1 Study of a Second Psilocybin Group Retreat for Partial Responders With Anxiety Associated With Metastatic Cancer - University of Washington (ClinicalTrials.gov, 2025)

Psilocybin and Affective Function in Chronic Lower Back Pain Depression - Johns Hopkins University (ClinicalTrials.gov, 2025)

Intravenous Administration of Serotonergic Psychedelics Produce Short-lasting Changes in Sleep-Wake Behavior and High Gamma Functional Connectivity in Rats - Kolbman N; Huels ER; Nelson A; Summerfield R; Byraju K; Groenhout T; Liu T; Hudetz AG; Vanini G; Pal D. (bioRxiv, 2025)

Psychedelic 5-HT2A receptor agonism alters neurovascular coupling and differentially affects neuronal and hemodynamic measures of brain function. - Padawer-Curry JA; Krentzman OJ; Kuo CC; Wang X; Bice AR; Nicol GE; Snyder AZ; Siegel JS; McCall JG; Bauer AQ. (2025)

Daily self-assessment within a regimen of microdosing indicates enhanced psychological functioning on microdosing days relative to non-microdosing days. - St Pierre M; Argento E; Cates J; Kryskow P; Harvey K; Stamets P; Santos-Brault E; Paschall SA; Kuypers KPC; Rootman J; Walsh Z (Psychopharmacology, 2025)

Set and setting in psilocybin-assisted therapy: A qualitative study of patients with cancer and depression - Yvan Beaussant; Elise C. Tarbi; Kabir Nigam; Skye A. Miner; Zachary Sager; Justin J. Sanders; Michael Ljuslin; Benjamin Guérin; Roxanne Sholevar; Kimberly Roddy; James A. Tulsky; Manish Agrawal (General Hospital Psychiatry, 2025)

Control group improvement lower in psilocybin trials for depression (The Brown University Psychopharmacology Update, 2025)

Psilocybin for Chronic Pelvic Pain (CPP) in Women: A Pilot Feasibility Study - Oregon Health; Science University (ClinicalTrials.gov, 2025)

Psilocybin’s effect on human brain synaptic plasticity - Johansen A; Plavén-Sigray P; Madsen MK; Søndergaard A; Messel C; Geisler M; Nasser A; McCulloch DE; Beliveau V; Vassilieva A; Lund A; Lehel S; et al. (Research Square, 2025)

The Research Deficit and Expert Disagreement Regarding Music Selection for Psychedelic Assisted Therapy. - Moskovitz M (ACS pharmacology & translational science, 2025)

Stabilizing Psilocybin Pharmacology and Tuning Safety with Atypical Antipsychotic Cotherapy. - Renner AC; Kargbo RB. (2025)

Corrigendum to "The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression" [Journal of Affective Disorders, Volume 372 (2025), Pages 523-532]. - Goodwin GM; Aaronson ST; Alvarez O; Carhart-Harris R; Chai-Rees J; Croal M; DeBattista C; Dunlop BW; Feifel D; Hellerstein DJ; Husain MI; Kelly JR; et al. (2025)

Toward Precision Psychedelic Therapies: Chemical, Computational, and Neuromodulatory Innovations. - Renner AC; Kargbo RB. (2025)

Neurocomputational evidence of sustained Self-Other mergence after psychedelics - Mallaroni P; Mason NL; Preller KH; Razi A; Ereira S; Ramaekers JG. (medRxiv, 2025)

Synaptic priming: A framework for pharmacotherapy in depression. - Brown KA; Ajibola MI; Medeiros GC; Gould TD. (2025)

A Pilot Study in North Louisiana to Assess the Tolerability of Psilocybin as Well as Its Capacity to Promote Abstinence From Methamphetamine - Kevin Murnane (ClinicalTrials.gov, 2025)

Efficacy of Psilocybin and Trazodone Combination in Treatment-resistant Depression: a Randomized Controlled Proof-of-concept Study (PSILOTRAZ) - Centre Hospitalier St Anne (ClinicalTrials.gov, 2025)

Towards Novel Antidepressant Strategies: A Comparative Study of Ketamine, Psilocybin, and Fluoxetine in a Chronic Stress Model - Domzalska M; Kwiatkowska J; Cichon I; Sokolowska E. (Research Square, 2025)

Neurobiological and Therapeutic Potential of Psilocybin in Psychiatric Disorders - M Loganathan; A Saravanakumar; P. Parthiban; G Anandharaj; S Gobika; D Dharshana; Mohamed Safir Ali (Journal of Pharma Insights and Research., 2025)

Harm reduction practises for users of psychedelic drugs: a scoping review. - Dutton C; North E; Chun Tie Y; Oliva J; Skeffington P (Harm reduction journal, 2025)

An Evaluation of Therapeutic Harm Reduction and Psilocybin-Assisted Therapy Within Oregon's Measure 109 - Bodhi Norton (PDXScholar (Portland State University), 2025)

Legal and Regulatory Barriers to Medical Psilocybin Use: An International Overview - Mohamad Chweikh (2025)

Retrospective Observational Study of Intensity Effects in Psychedelic-assisted Treatment - University Hospital; Geneva (ClinicalTrials.gov, 2025)

Single-dose psilocybin rapidly and sustainably relieves allodynia and anxiodepressive-like behaviors in mouse models of chronic pain - Ahmad Hammo; Stephen Wisser; Joseph Cichon (Nature Neuroscience, 2025)

Understanding psilocybin mushrooms and aiding in setting standards for a burgeoning industry in Jamaica - Rupika Delgoda; Kimberley Foster; Isaac Morrison; Marshall Tyler; William Irvine; Lavonne Wilson; Babumon M. Thankappan; Shemar Daniel (Phytochemistry Letters, 2025)

Psychedelics and autobiographical memory - six open questions. - Kangaslampi S; Lietz M (Psychopharmacology, 2025)

Psilocybin and MDMA for Post-traumatic Stress Disorder (PTSD) - Johns Hopkins University (ClinicalTrials.gov, 2025)

Gestational LSD exposure in mouse rapidly reaches embryonic CSF and is associated with altered choroid plexus signaling, cerebral cortical development, and offspring behavior - Courtney Y; Anderson JM; Lagares-Linares C; Wenthur CJ; Lehtinen MK. (bioRxiv, 2025)

Correction to: Incremental efficacy systematic review and meta-analysis of psilocybin-for-depression RCTs. - Borgogna NC; Owen T; Petrovitch D; Vaughn J; Johnson DAL; Pagano LA; Aita SL; Hill BD. (2025)

Clinical psychedelic research in adolescents: a scoping review and overview of ethical considerations. - Rajwani K; Jacobs E; Bruce L; Hokanson J; Almonte MT; Feroz F; Waldman E; Cheung K; Levy N; Savulescu J; Singh I; Yaden DB; et al. (2025)

Publisher Correction: Psilocybin's lasting action requires pyramidal cell types and 5-HT2A receptors. - Shao LX; Liao C; Davoudian PA; Savalia NK; Jiang Q; Wojtasiewicz C; Tan D; Nothnagel JD; Liu RJ; Woodburn SC; Bilash OM; Kim H; et al. (Nature, 2025)

Differential effects of psilocybin and lisuride on serotonin and dopamine neuronal activity and behavior - Brandon Richardson; Antonio Inserra; Michael Pileggi; Thomas Prudhomme; Vítor Bruno; Derek Wan-Yan-Chan; Ilia Shareghi-Ghahreman; Sofia Nasini; Tadhg Strand; Marco Leyton; Nahum Sonenberg; Danilo De Gregorio; et al. (Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2025)

Psilocybin during the postpartum period induces long-lasting adverse effects in both mothers and offspring - Cassandra J. Hatzipantelis; Min Liu; A. H. G. Love; Sadie J. Leventhal; Hero Maera; Srinidhi Viswanathan; Emily Avetisyan; Liana Belinsky; McKenna M. Rangel; Nina J. Jain; Max Kelly; C. Copeland; et al. (Nature Communications, 2025)

The transformational power of psychedelics: catalysts for creativity, consciousness, and mental health. - Du X; Liu J; Wang X; Wang X. (2025)

Ethical issues with psychedelic-assisted treatments in psychiatry: A systematic scoping review. - Caporuscio C; Poppe C; Gieselmann A; Repantis D. (2025)

An Exploratory Study of Feasibility, Efficacy, and Mechanisms of Mindfulness-Assisted Psychedelic Therapy - University of Southern California (ClinicalTrials.gov, 2025)

“So many relationships in the room”: Participant perspectives on the affordances and challenges of co-therapy in psychedelic assisted therapy (PsyArXiv, 2025)

Regional Specificity of the Cingulate Cortex Thickness Association with the Intensity of Psilocybin Experience: A Replication Study - Greguš D; Hlinka J; Tylš F; Viktorin V; Viktorinová M; Bravermanová A; Androvičová R; Andrashko V; Korčák J; Nikolič M; Adámek P; Beneš M; et al. (Research Square, 2025)

Psilocybin inhibits formalin-induced nociception through 5-hydroxytryptamine 2A receptor in rats - Saadet Inan; Paige E. Morris; Scott M. Rawls; Stephanie E. Daws (Behavioural Pharmacology, 2025)

Observational Pilot Study to Explore the Social and Health Impacts of a New Model of Care in Oregon: Psilocybin Services on Alcoholism - Healing Advocacy Fund (ClinicalTrials.gov, 2025)

Innovative Pharmacological Approaches to Eating Disorder Treatment. - Keshen A; Touyz S; Lacroix E; Hay P; McElroy SL. (2025)

Psilocybin-assisted psychotherapy in adults with depression - A literature review. - Dorczok MC; Mittmann G; Ettl T; Steiner-Hofbauer V. (2025)

Considerations and cautions for the integration of psilocybin into routine clinical care: a consensus statement from the US National Network of Depression Centers' Task Group on Psychedelics and Related Compounds. - Hosein MM; Reid MJ; Walser S; Charney S; Fonzo GA; Lewis BR; Yaden DB; Suppes T; Cordner ZA; Barrett FS. (2025)

Compassionate use of psilocybin for treatment-resistant depression in Germany - Gerhard Gründer; Lea J. Mertens; Andrea Jungaberle; Henrik Jungaberle; Moritz Spangemacher (The Lancet Psychiatry, 2025)

Electrodynamics of the Psychedelic Experience - Hunt T. (Preprints.org, 2025)

High dose of psilocybin induces acute behavioral changes without inducing conditioned place preference in Sprague-Dawley rats - Vítor Bruno; Martha López-Canul; Brandon Richardson; Rosana Camarini; Tânia Marcourakis; Gabriella Gobbi (Journal of Psychopharmacology, 2025)

Unterschiedliche Reaktionen und Enzyme in der Psilocybin- Biosynthese bei Inocybe- und Psilocybe -Pilzen - Tim Schäfer; Fabian Haun; Bernhard Rupp; Dirk Hoffmeister (Angewandte Chemie, 2025)

Dissimilar Reactions and Enzymes for Psilocybin Biosynthesis in Inocybe and Psilocybe Mushrooms - Tim Schäfer; Fabian Haun; Bernhard Rupp; Dirk Hoffmeister (Angewandte Chemie International Edition, 2025)

Psilocybin-assisted psychotherapy for methamphetamine use disorder: A pilot open-label safety and feasibility study - Elizabeth Knock; Krista J. Siefried; Gillinder Bedi; Steven M. Albert; Richard O. Day; Nadine Ezard; Margaret Ross; Paul Liknaitzky; Jonathan Brett (Addiction, 2025)

S1 Appendix - Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trial - Benjamin R. Lewis (22279166); John Hendrick (22279169); Kevin Byrne (1610821); Madeleine Odette (22279172); Chaorong Wu (8444343); Eric L. Garland (4666660) (Figshare, 2025)

Psychedelics Relax Priors and Reshape Orbitofrontal Dynamics - Delgado-Sallent C; Ahmed SA; Khawaja-Lopez A; Lee BS; Senne R; Scott BB; Ramirez S. (bioRxiv, 2025)

Reappraisal of the hype and hope offered by psilocybin treatment of depression. - Beaglehole B; Manuel J. (2025)

Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trial - Benjamin R. Lewis; John Hendrick; Kevin Byrne; Madeleine Odette; Chaorong Wu; Eric L. Garland (PLoS Medicine, 2025)

Evolution and Comparative Analysis of Clinical Trials on Psilocybin in the Treatment of Psychopathologies: Trends in the EU and the US - Anastasia Calin; Ana Flavia Burlec; Cornelia Mircea; Irina Macovei; Monica Hăncianu; Andreia Corciovă (Journal of Clinical Medicine, 2025)

PRoMiSS: Psilocybin and the Role of Music in Set and Setting - Johns Hopkins University (ClinicalTrials.gov, 2025)

Psilocybin ameliorates neuropathic pain-like behaviour in mice and facilitates gabapentin-mediated analgesia - Askey T; Allen-Ross D; Luzyanin D; Lasrado R; Gilmour G; Hunt SP; Tamagnini F; Ahmed M; Stephens GJ; Maiarú M. (bioRxiv, 2025)

The Impact of Psilocybin on Pain in Fibromyalgia Patients: a Multicentre Trial. - Maastricht University (ClinicalTrials.gov, 2025)

Multianalytical Investigation of Psilocybe cubensis Mushrooms: Physicochemical Characterization and Biological Evaluation of Psilocybin and Psilocin Compounds - Taynah Pereira Galdino; Antônio Braz de Medeiros Bisneto; Marcelo da Silva Pedro; Lucas Cordeiro de Oliveira; Mateus Araújo da Luz; Antônio Gilson Barbosa de Lima; Suédina Maria de Lima Silva; Marcus Vinícius Lia Fook (ACS Omega, 2025)

Dynamic myocardial injury and variable hallucination latency in Psilocybe keralensis poisoning: a molecularly confirmed case series from China - Zhifan He; Rui Tang; Min Feng; Xiaohui Li; Changhong Zhang; Jing Li (Clinical Toxicology, 2025)

Emerging mechanisms of psilocybin-induced neuroplasticity. - Sonda S; Pendin D; Comai S; De Martin S; Manfredi P; Mattarei A. (2025)

Temporal dynamics in neuroimaging as correlates of therapeutic response to psilocybin in major depressive disorder: A systematic review and critical appraisal. - Sabbah SG; Li S; Wong S; Le GH; Badulescu S; Hawco C; Rosenblat JD; McIntyre RS. (2025)

Microdosing Psychedelics to Restore Synaptic Density in Schizophrenia. - Sapienza J; Spangaro M; Comai S; Sabé M; La Torre J; Buonarroti M; Cavallaro R; Bosia M (International journal of molecular sciences, 2025)

Serotonin 5-HT2C Receptor Signaling Analysis Reveals Psychedelic Biased Agonism. - Bonniwell EM; Alabdali R; Hennessey JJ; McKee JL; Cavalco NG; Lammers JC; Moore EJ; Franchini L; Orlandi C; McCorvy JD. (2025)

Effective connectivity of the human claustrum: Triple networks, subcortical circuits, and psychedelic modulation - Masjedi NS; Razi A. (bioRxiv, 2025)

Mindset Over Molecule: Comparing Self-Transcendent and Mystical Experiences Across Recreational Psilocybin, MDMA, and Cannabis Use - Chwyl C; Spata A; Lucas W; Luoma JB. (Research Square, 2025)

Supporting Meaningful Choices: A Decision Aid for Individuals Facing Existential Distress and Considering Psilocybin-Assisted Therapy - Ariane Bélanger; Sue-Ling Chang; Jean-François Stephan; Florence Moureaux; Diane Tapp; Robert Foxman; Pierre Gagnon; Johanne Hébert; Houman Farzin; Michel Dorval (Healthcare, 2025)

Concomitant use of antidepressants and classic psychedelics: A scoping review. - Tap SC; Thomas K; Páleníček T; Stenbæk DS; Oliveira-Maia AJ; van Dalfsen JH; Schoevers RA. (2025)

Corrigendum to "Chronic psilocybin administration increases sociability and alters the gut microbiome in male wild-type mice but not in a preclinical model of obsessive-compulsive disorder" [Neuropharmacology 279 (2025) 110648]. - Gattuso JJ; Kong G; Bezcioglu B; Lu D; Ekwudo MN; Wilson C; Gubert C; Hannan AJ; Renoir T. (2025)

The Legal Perspective on Psilocybin for Medical Use in Czechia: A Key Milestone and the Case for Broader Consideration Beyond the Clinical Setting - Tereza Dleštíková (Psychoactives, 2025)

Active Constituents of Psilocybin Mushroom Edibles - Richard B. van Breemen; Daniel Simchuk; Bjorn Fritzsche; Daniel H. Huson; Scott Kuzdzal; J. W. Ferguson (JAMA Network Open, 2025)

Correction: Therapeutic and legal aspects of psilocybin in cancer-related depression. - Wierzbicka M; Kopczyk R; Gerlach A; Rymaszewska J. (2025)

Psilocybin Enhances Cued Fear Extinction and Extinction Recall in Stress-Naïve, Acutely Stressed, and Chronically Stressed Mice - John A. Razidlo; Noelle Cataldo; Cody J. Wenthur (ACS Pharmacology & Translational Science, 2025)

Measurement of Serum Cytokine Levels in Samples Collected as Part of a Clinical Trial of Psilocybin for Treatment-resistant Depression. - King's College London (ClinicalTrials.gov, 2025)

Processing Intergenerational Trauma With Psilocybin-Assisted Therapy - Rachel Yehuda (ClinicalTrials.gov, 2025)

Effect of psilocybin therapy on suicidal ideation, attempts, and deaths in people with psychiatric diagnoses: a systematic review and meta-analysis. - Wong S; Meckling G; Fabiano N; Lee S; Jones BDM; Shorr R; Dargel A; Davis AK; Fiedorowicz JG; Solmi M; Rosenblat JD; Mulsant BH; et al. (2025)

Five-year outcomes of psilocybin-assisted therapy for Major Depressive Disorder - Alan K. Davis; Meghan DellaCrosse; Nathan D. Sepeda; Adam W. Levin; Mary P Cosimano; Hillary Shaub; Washington Taylor; Peter M. Gooch; Shoval Gilead; Skylar J. Gaughan; Stacey B. Armstrong; Frederick S. Barrett (Journal of Psychedelic Studies, 2025)

Blunted psychedelic drug effects in older adults - Aday JS; Carhart-Harris R; Boehnke KF. (PsyArXiv, 2025)

Blunted psychedelic drug effects in older adults (PsyArXiv, 2025)

Therapeutic Use of Psilocybin in Depression: a Systematic Review of Clinical Evidence. - Andrade FRT; Buchborn T; Thalheimer G; Meinhardt MW; Joca S; de Almeida RMM. (2025)

Reply to Gattuso et al.: "Comments on 'Striking long-term beneficial effects of single-dose psilocybin and psychedelic mushroom extract in the SAPAP3 rodent model of OCD-like excessive self-grooming' by Brownstien et al. (2024)". - Brownstien M; Lazar M; Botvinnik A; Pogodin I; Lifschytz T; Lerer B. (2025)

Effect of Psilocybin Only and Psilocybin Assisted Cognitive Behavioral Therapy in the Management of Major Depressive Disorder and Associated Metabolic, Immune, Inflammatory, Neuroplasticity and Electrical Activity Markers: a Randomized Controlled Trial - Khyber Medical University Peshawar (ClinicalTrials.gov, 2025)

We may know why psilocybin helps treat mental health conditions - Chris Simms (The New Scientist, 2025)

Psilocybin-Assisted Psychotherapy for Chronic Somatoform Pain Disorder: A Case Report - M Mercier; Cédric Mabilais; Vasileios Chytas; Leonice Furtado; Federico Seragnoli; Albert Buchard; Tatiana Aboulafia Brakha; Gabriel Thorens; Daniele Zullino; Louise Penzenstadler (Psychoactives, 2025)

PSYCHEDELICS IN PSYCHIATRY - OVERVIEW OF PSILOCYBIN RESEARCH - Anna Blazhkova; Magdalena Czaja; Hanna Sitka; Sven Solisch; Anna Susłow; Ewa Szczęsna (International Journal of Innovative Technologies in Social Science, 2025)

Biochemical Insights into Diverse Psilocybe Mushrooms and Their Metabolites as Sources of Neuroactive Agents: A Review - Sudhakaran G; Chakraborty S; Aung San; Bharti SAK; Csaba V; Valan Arasu M; Namasivayam SKR; Arockiaraj J. (2025)

Separate or inseparable? Serotonin and dopamine system interactions may underlie the therapeutic potential of psilocybin for anorexia nervosa - McCoy K; Reed F; Conn K; Foldi CJ. (2025)

“Wood-lover paralysis”: Describing a toxidrome with symptoms of weakness caused by some lignicolous “wood-loving” Psilocybe mushrooms - Beck SA; Barlow C; Engel L; Barratt MJ. (2025)

Psilocybin Use in the Autism Spectrum Disorder: A Scoping Review - Jaime Moreno-Chaparro; Gabriela Castañeda-Millán; Javier Eslava-Schmalbach (Clinical Neuropharmacology, 2025)

Psilocybin with psychotherapeutic support for treatment-resistant depression: a pilot clinical trial - Sally Meikle; Olivia Carter; Paul Liknaitzky; Lauren Johansen; Ravi Iyer; Nigel Strauss; M.L. Williams; David Castle; Susan L. Rossell (Therapeutic Advances in Psychopharmacology, 2025)

US Poison Center Encounters for Psilocybin-Related Exposures: 2013-2022 - Juan Carlos C. Montoy; Ralph C. Wang; Allison R. Coker; Craig G. Smollin; B. Anderson (Journal of the American College of Emergency Physicians Open, 2025)

Psilocybin-assisted therapy for treatment-resistant depression in the US: a model-based cost-effectiveness analysis - Anton L.V. Avanceña; Linh N. Vuong; James G. Kahn; Elliot Marseille (Translational Psychiatry, 2025)

Investigating the safety and tolerability of single-dose psilocybin for post-traumatic stress disorder: A nonrandomized open-label clinical trial - Niall M. McGowan; James Rucker; Rachel Yehuda; Manish Agrawal; Nadav Liam Modlin; Hollie Simmons; Agata Tofil-Kaluza; Shriya Das; Guy M. Goodwin (Journal of Psychopharmacology, 2025)

A Phase 2 Single-site, Double-blind, Placebo-controlled, Randomized Clinical Trial With an Open-label Extension Phase to Examine the Safety, Subjective Experiences, Acute Effects, and Suitability of Psilocybin Combined With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring Alcohol Use Disorder (AUD) and Posttraumatic Stress Disorder (PTSD) - Nathan Brashares Sackett (ClinicalTrials.gov, 2025)

Overview and Specificity of Psilocybin Use in the Treatment of Mental Disorders: A Scientometric Analysis. - Fernandes-Nascimento MH; Viana-Ferreira K; Negrão AB. (2025)

Unsupervised Extractive Summarization of Psychedelic User Experience Reports - Islam S; Salam S; Hasan MN. (medRxiv, 2025)

Pharmacological characterisation of psilocybin and 5-MeO-DMT discriminative cues in the rat and their translational value for identifying novel psychedelics - Guy A. Higgins; Cam MacMillan; Inés de Lannoy; Carolyn M. Tyler; Malik Slassi (Journal of Psychopharmacology, 2025)

Psilocybin: Systematic review of its use in the treatment of depression - Andres-Olivera P; de la Iglesia J; Dominguez-Alvarez E; Soto’Gonzalez P; Rodriguez C; Munaiz-Cossio C; Gonzalez-Bolaños R; Brito-Rey R; Marín-Lorenzo C; Arribas-Simon B. (2025)

Short- and long-term modulation of rat prefrontal cortical activity following single doses of psilocybin - Ross J. Purple; Rahul Gupta; Christopher W. Thomas; Caroline T. Golden; Nicola Palomero-Gallagher; Robin Carhartt-Harris; Seán Froudist-Walsh; Matthew W. Jones (Molecular Psychiatry, 2025)

“To Have the Encounter with Our Own Finiteness in that Existential Way”: Descriptions of Existential Experience in Patients with Cancer and Major Depression Participating in Psilocybin-Assisted Group Therapy - Elise C. Tarbi; Skye A. Miner; Kabir Nigam; Zachary Sager; Justin J. Sanders; Michael Ljuslin; Benjamin Guérin; Kimberly Roddy; James A. Tulsky; Manish Agrawal; Yvan Beaussant (Psychedelic Medicine, 2025)

Above the threshold, beyond the trip: the role of the 5-HT2A receptor in psychedelic-induced neuroplasticity and antidepressant effects. - Drewko AJ; Habets RLP; Brunt TM. (2025)

Context-dependent structurally informed effective connectivity under psilocybin - Greaves MD; Barta T; Novelli L; Stoliker D; Razi A. (bioRxiv, 2025)

Psychedelic Therapy, Positive Emotional Experiences, and the Central Role of Self-Compassion - Zeifman R; Danias G; Agin-Liebes G; Pagni B; Kettner H; Bhat V; Ross S; Erritzoe D; Carhart-Harris R. (Research Square, 2025)

Evaluation of the Effect of a Single Dose of Psilocybin on Neural Correlates of Cognitive Control in Patients With Psychogenic Nonepileptic Seizures - Centre Hospitalier Universitaire de Nīmes (ClinicalTrials.gov, 2025)

Psychedelics and the Serotonin Hypothesis of Eating Disorders. - Bilenker D; Avena NM. (2025)

Chronic psilocybin administration increases sociability and alters the gut microbiome in male wild-type mice but not in a preclinical model of obsessive-compulsive disorder - James J Gattuso; Geraldine Kong; Bilgenur Bezcioglu; Da Lu; Millicent N. Ekwudo; Carey Wilson; Carolina Gubert; Anthony J. Hannan; Thibault Renoir (Neuropharmacology, 2025)

Effect of Psilocybin on the Positive Valence System in Treatment-resistant Depression: a Pilot Clinical Neuroimaging Study - Centre Hospitalier Universitaire de Nīmes (ClinicalTrials.gov, 2025)

Effects of Psilocybin in Post-Treatment Lyme Disease - Johns Hopkins University (ClinicalTrials.gov, 2025)

Psilocybin-assisted psychotherapy, combined antipsychotic and antidepressant treatment for bipolar depression, duration of birth control pill use and risk of depression, handgrip strength and cognitive function, mood disorders in epilepsy, and mental health issues among physicians. - Koenig HG. (2025)

A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder - COMPASS Pathways (ClinicalTrials.gov, 2025)

Attitudes Toward Psychedelic-Assisted Therapies for Cancer-Related Psychosocial Symptoms: A Multi- Stakeholder Analysis - Schuman HD; Deleemans JM; Nguyen T; Savard C; Mina R; Carlson LE. (Research Square, 2025)

Serotonin and psilocybin activate 5-HT1B receptors to suppress cortical signaling through the claustrum - Maxwell B. Madden; Chloe Schaefgen; Binita Vedak; Jian Kwon; Kiara S. Dresp Pedra; Samuel H. Sheats; Adam C. Puché; Steffen B. E. Wolff; Brian N. Mathur (Nature Communications, 2025)

Exploring the therapeutic potential of psychedelics in treating substance use disorders. - Li Y; Li H; Wang H; Wang X. (2025)

Psychedelic-assisted therapies for existential and spiritual suffering in palliative care. - Garcia ACM; Maia LO. (2025)

Exploring the Therapeutic Potential of Ketamine and Psilocybin in Comparison to Current Treatment Regimens for Treatment-Resistant Depression, Mood Disorders, and Post-traumatic Stress Disorder in the Pediatric Population: A Narrative Review. - Hughes B; Mirza S; Ponamala M; Sagaser J; Paredes R; Hematillake N; Tailor C; Khan R; Pemminati S. (2025)

Psilocybin treatment for symptoms of depression: a living systematic review, meta-analysis, and data resource - Singleton SP; Sevchik BL; Lahey A; Cuijpers P; Harrer M; Jones MT; Nayak SM; Strain EC; Vandekar SN; Dworkin RH; Scott JC; Satterthwaite TD. (medRxiv, 2025)

Therapeutic Divergence in 5-HT2A Agonism: Psilocybin and Phenalkylamines for Demoralization Syndrome. - Kargbo RB. (2025)

Toward Standardized Products Containing Biomass of Psilocybe Cubensis Fungi - Kimberley Foster; Isaac Morrison; Shemar Daniel; Johann M.R. Antoine; Babumon M. Thankappan; Winston De La Haye; Marshall Tyler; Charles N. Grant; Rupika Delgoda (Journal of AOAC International, 2025)

Psilocybin-assisted psychotherapy for depression and anxiety associated with life threatening illness: A phase 2b randomized controlled trial - Margaret Ross; Ravi Iyer; M.L. Williams; Mark Boughey; Clare O’Callaghan; Richard Hiscock; Justin Dwyer (General Hospital Psychiatry, 2025)

Psychedelic-Assisted Therapy: Potential Benefits and Challenges in Mental Health Treatment. - Silczuk A; Madejek RJ; Koweszko T; Mularczyk-Tomczewska P; Adamska E; Gujski M; Szulc A. (2025)

Psychedelics and Headache Disorders: an Update. - Im JJH; Sandoe CH (Current neurology and neuroscience reports, 2025)

The psychedelic renaissance: psilocybin, a breakthrough for treatment resistant depression? - Trevor R. Norman (Exploration of neuroscience, 2025)

Substance Abuse and Cognitive Decline: The Critical Role of Tau Protein as a Potential Biomarker. - Rebolledo-Pérez L; Hernández-Bello J; Martínez-Ramos A; Castañeda-Arellano R; Fernández-Quezada D; Sandoval-García F; Aguilar-García IG. (2025)

Psilocybin triggers an activity-dependent rewiring of large-scale cortical networks - Jiang Q; Shao L; Yao S; Savalia NK; Gilbert AD; Davoudian PA; Nothnagel JD; Tian G; Hung TS; Lai H; Beier KT; Zeng H; et al. (bioRxiv, 2025)

Psychedelics and the Gut Microbiome: Unraveling the Interplay and Therapeutic Implications. - Wang X; Jun F; Lin C; Wang X (ACS chemical neuroscience, 2025)

Improved mental health outcomes and normalised spontaneous EEG activity in veterans reporting a history of traumatic brain injuries following participation in a psilocybin retreat - Grace Blest-Hopley; Giuseppe Pasculli; Simon Ruffell; WaiFung Tsang; Olateju Emmanuel; Kathryn M. Pate; Hannes Kettner; Leor Roseman; David Erritzøe; Robin Carhart-Harris (Frontiers in Psychiatry, 2025)

Between enhancement and risk: A critical review of psychedelic microdosing. - Totomanova I; Haijen ECHM; Hurks PPM; Ramaekers JG; Kuypers KPC. (2025)

Neurobiology of psilocybin: a comprehensive overview and comparative analysis of experimental models - Dotun Adeleye Adeyinka; Dayna Forsyth; Suzanne Currie; Nicoletta Faraone (Frontiers in Systems Neuroscience, 2025)

A dose of therapy with psilocybin - A meta-analysis of the relationship between the amount of therapy hours and treatment outcomes in psychedelic-assisted therapy. - Hultgren J; Hafsteinsson MH; Brulin JG. (2025)

Response to emotional stimuli weaker in SSRI users compared with psilocybin (The Brown University Psychopharmacology Update, 2025)